Home
A Busy Month in the Business of microRNA

A Busy Month in the Business of microRNA

| June 30, 2010 |
A Busy Month in the Business of microRNA

BUSINESSWIRE –

June 29th – Alnylam Obtains Approvals to Initiate Phase I Study with ALN-TTR01 in Patients with TTR-Mediated Amyloidosis (ATTR)

June 29th – Mirna Therapeutics Publishes Data Demonstrating In Vivo Proof of Concept for miR-34a microRNA Replacement Therapy in Cancer

June 28th – Reimbursement for Rosetta Genomics’ miRview™ mets Test Now Available in Israel Through World’s Second Largest HMO

June 28th – Alnylam Scientists and Collaborators Publish Research in Nature Chemical Biology on a Novel Mechanism for Regulation of Gene Expression with Anti-Gene RNAs (agRNAs)

June 23rd – Santaris Pharma A/S and miRagen Therapeutics, Inc. Form Strategic Alliance to Develop microRNA-Targeted Medicines for the Treatment of Cardiovascular Disease

June 23rd – Alnylam Biotherapeutics Presents New Data on RNAi Applications in Biotherapeutics Manufacturing

June 22nd – Isis and Alnylam Provide Update on Regulus’ Strategic Alliance with Sanofi-Aventis

June 22nd – Sanofi-Aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA Therapeutics

June 21st – Mirna Therapeutics Recommended for $10 Million Commercialization Award from the Cancer Prevention and Research Institute of Texas

June 17th – Alnylam Secures Intellectual Property and Technology for RNAi Applications in Vaccine Research and Development

June 17th – Alnylam Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Broadly Covering RNAi Therapeutics that Target Mutated Genes

June 7th – Data Presented at ASCO 2010 by M. D. Anderson Researchers Demonstrate the ability of miRview™ mets to Identify the Most Likely Origin of Metastases in Cancer of Unknown Primary

June 3rd – Rosetta Genomics Establishes “Rosetta Green” as Majority-owned Subsidiary

Subscribe to the miRNA blog

Thank you for subscribing.

Something went wrong.

We respect your privacy and take protecting it seriously

Related Posts

One Response

  1. Anonymous
    July 8, 2010

    Looks as if we missed one:
    June 23rd – Santaris Pharma A/S and miRagen Therapeutics, Inc. Form Strategic Alliance to Develop microRNA-Targeted Medicines for the Treatment of Cardiovascular Disease

    http://www.prnewswire.com/news-releases/santaris-pharma-as-and-miragen-therapeutics-inc-form-strategic-alliance-to-develop-microrna-targeted-medicines-for-the-treatment-of-cardiovascular-disease-96964249.html

    Thanks go to Anna & Bruce for pointing it out!

Add Comment